Combined Holdings of Beam Therapeutics (BEAM) - Updated Daily
TherapeuticsGene TherapyGenomicsGene Base Editing
Key Statistics
Statistics
| ⚖️Weighting | 🧢Market Cap |
|---|---|
| 1.98% | $2.25b |
| 🏋️♀️Weight Rank Across All Funds | 🌏Country |
| 18 | 🇺🇸United States |
| 💳ARK Estimated Cost Average | 🎫ARK Ownership Percent |
- ARKG - ARKK | 11.26% |
| Description | |
|---|---|
| Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases. | |
| Website | |
| beamtx.com |
Other ETFs That Hold BEAM
Research Notes and Commentary for BEAM
January 19, 2021